GlaxoSmithKlineGlaxoSmithKline Corporate and Social Responsibility Report 2002
Reporting Front PageDownloads
CSR 2002 home
A global challenge
The scope of our business
Our contribution to society
Case Study
Medicines for the developing world
Community investment
Research & development
Valuing people
Environment, health and safety
Business ethics and integrity
Management of CSR
Web references
Corporate Social Responsibility Committee
Case study

Asthma-related deaths and hospital admissions have declined, but the incidence of asthma is growing. Asthma remains a major health issue worldwide. We focus on what matters to patients, concentrating on their quality of life.
Previous
Next
 


Development of our asthma treatmentsDr Vincent McGovern, a General Practitioner in Belfast, UK, gives his perspective on asthma management as both a patient and a doctor.
A Patient’s Perspective
– “The management asthma has changed dramatically over the last 30 years. I was the child who wanted to play football, but had to play in goal, who had rounded shoulders and a blue inhaler in every pocket. I remember sleepless nights with emergency visits from the doctor. When inhaled steroids became available they took away the sleepless nights. The development of new treatments has made a huge impact on my life. I still have asthma, but it’s well controlled by preventative treatments. I certainly don’t notice have it, and nobody else does either.”

A Doctor’s Perspective – “As a GP who is also an asthmatic, I find asthma a really satisfying condition to treat. It is common, with 5.1 million sufferers in the UK. In my practice, 80 per cent of the asthmatics will have mild-to-moderate disease. I aim to achieve total control of their symptoms using current treatments, giving them a good quality of life. And the standard of patient care is getting higher, either through specialised units or one-to one consultations with nurses or doctors. Asthma is an area where national treatment guidelines have been adopted and have had a major impact on disease management.”

Over the last 30 years our R&D organisation has produced improved medicines to treat asthma and better ways for them to be taken. These advances have been vital in enabling healthcare professionals to provide ever-improving patient care. However, asthma still causes suffering and even death, so we will continue our research with the aim of further improving the lives of the growing number of people affected by this disease.

Previous
Next


Top


CSR 2002 Home | Reporting Front Page | Downloads | Main Site

 
Updated March 28, 2003 - © 2005 GlaxoSmithKline - All Rights Reserved
Legal Notices - Privacy Statement